Literature DB >> 7972232

Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment.

G M Brodeur1, J Pritchard, F Berthold, N L Carlsen, V Castel, R P Castelberry, B De Bernardi, A E Evans, M Favrot, F Hedborg.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7972232

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN： 0361-7742


× No keyword cloud information.
  23 in total

1.  Identifying altered gene expression in neuroblastoma cells preceding apoptosis.

Authors:  Piruz Nahreini; Xiang-Dong Yan; Cynthia P Andreatta; Kedar N Prasad; Neil W Toribara
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-05       Impact factor: 4.553

2.  PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.

Authors:  Joanna E Gawecka; Dirk Geerts; Jan Koster; Maisel J Caliva; Florian J Sulzmaier; John Opoku-Ansah; Randal K Wada; André S Bachmann; Joe W Ramos
Journal:  Int J Cancer       Date:  2012-01-31       Impact factor: 7.396

3.  Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas.

Authors:  M Krams; A Claviez; K Heidorn; G Krupp; R Parwaresch; D Harms; P Rudolph
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  Association of image-defined risk factors, tumor resectability, and prognosis in children with localized neuroblastoma.

Authors:  An-An Zhang; Ci Pan; Min Xu; Xiao-Xia Wang; Qi-Dong Ye; Yi-Jin Gao; Jing-Yan Tang
Journal:  World J Pediatr       Date:  2019-07-24       Impact factor: 2.764

5.  High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.

Authors:  Pramila Ramani; Scott Taylor; Elizabeth Miller; Emile Sowa-Avugrah; Margaret T May
Journal:  J Histochem Cytochem       Date:  2015-02-23       Impact factor: 2.479

6.  High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas.

Authors:  Pramila Ramani; Emile Sowa-Avugrah; Margaret T May
Journal:  Virchows Arch       Date:  2015-07-22       Impact factor: 4.064

7.  Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma.

Authors:  Matthias Krams; Barbara Hero; Frank Berthold; Reza Parwaresch; Dieter Harms; Pierre Rudolph
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

8.  Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

Authors:  Barry J Maurer; Min H Kang; Judith G Villablanca; Jitka Janeba; Susan Groshen; Katherine K Matthay; Paul M Sondel; John M Maris; Hollie A Jackson; Fariba Goodarzian; Hiroyuki Shimada; Scarlett Czarnecki; Beth Hasenauer; C Patrick Reynolds; Araz Marachelian
Journal:  Pediatr Blood Cancer       Date:  2013-06-29       Impact factor: 3.167

9.  Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.

Authors:  Ali Mazloom; Chrystal U Louis; Jed Nuchtern; Eugene Kim; Heidi Russell; Wendy Allen-Rhoades; Robert Krance; Arnold C Paulino
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-09-20       Impact factor: 7.038

10.  Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981-2000: a population-based study.

Authors:  H Schroeder; J Wacher; H Larsson; S Rosthoej; C Rechnitzer; B L Petersen; B L Pedersen; N L T Carlsen
Journal:  Br J Cancer       Date:  2009-02-17       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.